Generics Bulletin
Alembic Remains Upbeat Despite Rhizen Setback
By Anju Ghangurde 17 May 2022
Disappointment for Alembic-backed Rhizen after partner TG Therapeutics takes Ukoniq off the US market amid wider regulatory scrutiny around the...
Generics Bulletin
By Anju Ghangurde 17 May 2022
Disappointment for Alembic-backed Rhizen after partner TG Therapeutics takes Ukoniq off the US market amid wider regulatory scrutiny around the...
Generics Bulletin
By Dean Rudge 17 May 2022
Endo maintains that it will continue to drive revenue and EBITDA growth via business development opportunities, after the advent of...
Generics Bulletin
By David Wallace 17 May 2022
Japan’s Nippon Chemiphar and the International Finance Corporation have announced an alliance that will see the pair collaborate to boost...
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Contact us for product technical and account support.
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: